Main Outcomes and Measures The pilot outcomes of the trial were retention, acceptability, tolerability, and estimates of putative treatment effect on clinical symptoms (depression: Hamilton Depression Rating Scale and Inventory of Depressive Symptomatology scores anxiety: Hamilton Anxiety Rating Scale and General Anxiety Disorder scores) to be used as indicators for a definitive trial. Intervention Multistrain probiotic (8 billion colony-forming units per day) or placebo daily for 8 weeks added to ongoing antidepressant medication. Data were collected between September 2019 and May 2022 and analyzed between July and September 2022. A random sample was recruited from primary and secondary care services and general advertising in London, United Kingdom. Objective To provide acceptability and tolerability data and estimates of intervention effect size for probiotics as adjunctive treatment for patients with major depressive disorder (MDD).ĭesign, Setting, and Participants In this single-center, double-blind, placebo-controlled pilot randomized clinical trial, adults aged 18 to 55 years with MDD taking antidepressant medication but having an incomplete response were studied. However, few clinical trials have been conducted, and further safety and efficacy data are needed to support this treatment approach. Importance The microbiota-gut-brain axis is a promising target for novel treatments for mood disorders, such as probiotics. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.
Challenges in Clinical Electrocardiography.
0 kommentar(er)
